At #AACR26, Henlius presented new data on HLX3902 (CD3×CD28×STEAP1 tri-specific #TCE), demonstrating best-in-class potential in prostate cancer. our in-house multispecific #TCE platform aims to overcome key barriers in #SolidTumor treatment.

Link: https://t.co/qWzWGA0nlQ https://t.co/UshEbd9Qma